Therefore, it is similar in principle to the approved CAR T-cell therapies used in cancer therapy, such as Kymriah and ...

Gilead Sciences presents five-year Phase II ZUMA-5 trial results for Yescarta in relapsed non-Hodgkin lymphomas, showing a 90 ...

Kite unit reported positive results from a five-year follow-up of a Phase 2 study for its cell therapy Yescarta in certain ...

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

Kite, a Gilead Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory no ...

Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or ...

This early data has demonstrated a clear improvement in GLPG5101 efficacy over its competitors in iNHL and MCL.

Analysts at RBC Capital Markets said that moving Yescarta into the second-line setting alone could double the market opportunity for Gilead, and bump its CAR-T franchise up to peak sales of $1.8 ...

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novartis ...

Lymphoma patients better tolerated the CAR T-cell therapy manufactured on site at the Sheba Medical Center than they did the ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...